% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Amitay:153167,
      author       = {E. Amitay$^*$ and P. R. Carr$^*$ and L. Jansen$^*$ and E.
                      Alwers$^*$ and W. Roth and E. Herpel and M. Kloor and H.
                      Bläker and J. Chang-Claude$^*$ and H. Brenner$^*$ and M.
                      Hoffmeister$^*$},
      title        = {{P}ostmenopausal hormone replacement therapy and colorectal
                      cancer risk by molecular subtypes and pathways.},
      journal      = {International journal of cancer},
      volume       = {147},
      number       = {4},
      issn         = {1097-0215},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2020-00220},
      pages        = {1018-1026},
      year         = {2020},
      note         = {2020 Aug 15;147(4):1018-1026#EA:C070#LA:C070#},
      abstract     = {Postmenopausal hormone replacement therapy (HRT) was found
                      to be associated with lower risk of colorectal cancer (CRC).
                      However, little is known regarding associations with
                      molecular subtypes of CRC. The current study includes female
                      participants of a large German population-based case-control
                      study (922 CRC cases and 1,183 controls). Tumor tissue
                      samples were analyzed for microsatellite instability (MSI),
                      CpG island methylator phenotype (CIMP), BRAF and KRAS
                      mutation status. Multivariable logistic regression models
                      were used to assess the association of HRT use with
                      molecular subtypes and pathways. Postmenopausal HRT use was
                      overall associated with reduced risk of CRC (adjusted
                      odds-ratio (aOR) 0.62, $95\%$ confidence interval (CI)
                      0.50-0.76) and no major differences were observed for
                      molecular subtypes or for tumor marker combinations
                      representing molecular pathways. When stratified by median
                      age (≤/>71 years) potentially stronger risk reductions
                      were observed in the older group for subtypes showing MSI
                      (OR = 0.36, $95\%CI$ 0.17-0.76), BRAF mutation
                      (OR = 0.40, $95\%CI$ 0.30-0.83) and CIMP-high
                      (OR = 0.40, $95\%CI$ 0.21-0.73) and for CRC suggestive of
                      the sessile serrated pathway (OR = 0.45, $95\%CI$
                      0.20-1.01). In conclusion, postmenopausal use of HRT was
                      similarly associated with risk reduction of major molecular
                      tumor subtypes and pathways of CRC. Potentially stronger
                      risk reductions with CRC subtypes diagnosed at higher ages
                      require confirmation and clarification from other studies.
                      The current study extends the limited understanding of the
                      mechanisms of HRT in CRC prevention. This article is
                      protected by copyright. All rights reserved.},
      cin          = {C070 / C120 / HD01 / C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
                      I:(DE-He78)HD01-20160331 / I:(DE-He78)C020-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31943160},
      doi          = {10.1002/ijc.32868},
      url          = {https://inrepo02.dkfz.de/record/153167},
}